[
  {
    "objectID": "targets/tigit.html",
    "href": "targets/tigit.html",
    "title": "TIGIT",
    "section": "",
    "text": "Note\n\n\n\nTIGIT ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ"
  },
  {
    "objectID": "targets/tigit.html#monitoring-status",
    "href": "targets/tigit.html#monitoring-status",
    "title": "TIGIT",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT04818619\nAssiut University\nüü¢ No Change\nUNKNOWN\nChronic Myeloid Leukemia\nN/A\n2021-04\n2022-12\n65\n2021-03-25\n\n\nNCT04150965\nMultiple Myeloma Research Consortium\nüü¢ No Change\nTERMINATED\nMultiple Myeloma, Relapsed Refractory Multiple Myeloma\nPHASE1, PHASE2\n2020-07-10\n2024-08-30\n14\n2025-02-12\n\n\nNCT05607563\nBiotheus Inc.\nüü¢ No Change\nUNKNOWN\nAdvanced Tumor\nPHASE1\n2022-11-21\n2023-12\n54\n2023-02-07\n\n\nNCT05394168\nShanghai Henlius Biotech\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced/Metastatic Solid Tumors\nPHASE1\n2022-12-09\n2025-03-04\n12\n2024-03-28\n\n\nNCT07171307\nInstituto de Oftalmolog√≠a Fundaci√≥n Conde de Valenciana\nüü¢ No Change\nNOT_YET_RECRUITING\nConjunctivitis, Allergic\nN/A\n2026-01-01\n2026-09\n60\n2025-09-15\n\n\nNCT04995523\nAstraZeneca\nüü¢ No Change\nRECRUITING\nNon-Small-Cell Lung Carcinoma\nPHASE1, PHASE2\n2021-09-14\n2028-03-16\n210\n2025-11-21\n\n\nNCT03119428\nOncoMed Pharmaceuticals, Inc.\nüü¢ No Change\nTERMINATED\nLocally Advanced Cancer, Metastatic Cancer\nPHASE1\n2017-05-02\n2019-05-15\n33\n2020-08-10\n\n\nNCT04500678\nUniversity of Hawaii\nüü¢ No Change\nUNKNOWN\nHIV/AIDS\nPHASE2, PHASE3\n2019-02-01\n2022-12-31\n38\n2020-08-04\n\n\nNCT05483400\nUniversity Medical Center Groningen\nüü¢ No Change\nRECRUITING\nHead and Neck Neoplasms, MSI-H Cancer, Melanoma\nPHASE2\n2023-10-18\n2027-09\n97\n2025-03-28\n\n\nNCT05390528\nShanghai Henlius Biotech\nüü¢ No Change\nUNKNOWN\nAdvanced Tumors, Lymphoma, Metastatic Tumors\nPHASE1, PHASE2\n2022-06-20\n2024-12-30\n30\n2023-08-07\n\n\nNCT06250036\nRoyal Marsden NHS Foundation Trust\nüü¢ No Change\nRECRUITING\nLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer\nPHASE2\n2025-02-20\n2031-09-01\n50\n2025-08-19\n\n\nNCT05653284\nAkeso\nüü¢ No Change\nCOMPLETED\nAdvanced Malignant Tumors\nPHASE1\n2023-02-09\n2024-05-30\n19\n2024-08-11\n\n\nNCT05102214\nShanghai Henlius Biotech\nüü¢ No Change\nUNKNOWN\nLocally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2022-05-03\n2024-02\n150\n2023-08-07\n\n\nNCT05023109\nShanghai Zhongshan Hospital\nüü¢ No Change\nUNKNOWN\nBiliary Tract Carcinoma\nPHASE2\n2021-02-01\n2024-12-01\n45\n2023-08-12\n\n\nNCT05130177\nDiwakar Davar\nüü¢ No Change\nRECRUITING\nMelanoma\nPHASE2\n2022-03-16\n2031-01\n26\n2025-05-02\n\n\nNCT04047862\nBeiGene\nüü¢ No Change\nCOMPLETED\nLocally Advanced and Metastatic Solid Tumors\nPHASE1\n2019-08-15\n2024-08-07\n446\n2025-08-04\n\n\nNCT05537051\nBiotheus Inc.\nüü¢ No Change\nUNKNOWN\nAdvanced Solid Tumours\nPHASE1\n2023-10-30\n2025-12-31\n30\n2023-02-07\n\n\nNCT05019677\nFudan University\nüü¢ No Change\nWITHDRAWN\nIntrahepatic Cholangiocarcinoma\nPHASE2\n2021-09-01\n2024-12-01\n0\n2022-03-22\n\n\nNCT05061628\nShanghai Junshi Bioscience Co., Ltd.\nüü¢ No Change\nUNKNOWN\nAdvanced Tumors\nPHASE1\n2021-04-21\n2024-09-30\n176\n2021-09-21\n\n\nNCT04656535\nYale University\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nEARLY_PHASE1\n2021-04-21\n2026-12-31\n46\n2026-01-06\n\n\nNCT06773507\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nüü¢ No Change\nRECRUITING\nAdvanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)\nPHASE1\n2025-05-12\n2027-06\n80\n2025-07-07\n\n\nNCT06349980\nShanghai Henlius Biotech\nüü¢ No Change\nRECRUITING\nCarcinoma, Hepatocellular\nPHASE2\n2024-08-05\n2027-02-10\n117\n2024-12-15\n\n\nNCT05706207\nHuabo Biopharm Co., Ltd.\nüü¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-12-21\n2023-09-30\n36\n2023-01-20\n\n\nNCT05060432\niTeos Belgium SA\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma\nPHASE1, PHASE2\n2021-09-06\n2025-07\n153\n2024-06-19\n\n\nNCT06713798\nGustave Roussy, Cancer Campus, Grand Paris\nüü¢ No Change\nNOT_YET_RECRUITING\nMetastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer\nPHASE2\n2025-07\n2030-01\n115\n2025-06-23\n\n\nNCT05394337\nM.D.¬†Anderson Cancer Center\nüü¢ No Change\nRECRUITING\nMetastatic Malignancy\nPHASE1, PHASE2\n2023-02-23\n2025-12-31\n10\n2025-10-07\n\n\nNCT05253105\nShanghai Junshi Bioscience Co., Ltd.\nüü¢ No Change\nWITHDRAWN\nPreviously Treated, Advanced, Malignancies\nPHASE1\n2022-03-15\n2027-01\n0\n2022-05-24\n\n\nNCT04270942\nProvention Bio, a Sanofi Company\nüü¢ No Change\nCOMPLETED\nDiabetes Mellitus, Type 1\nPHASE2\n2020-02-26\n2024-01-22\n6\n2025-01-20\n\n\nNCT05294952\nAssiut University\nüü¢ No Change\nNOT_YET_RECRUITING\nPre-Eclampsia\nPHASE4\n2025-01-01\n2025-11-04\n82\n2024-02-01\n\n\nNCT06754501\nM.D.¬†Anderson Cancer Center\nüü¢ No Change\nRECRUITING\nCancer\nPHASE2\n2025-04-11\n2029-07-01\n35\n2025-10-01\n\n\nNCT05757492\nCoherus Oncology, Inc.\nüü¢ No Change\nTERMINATED\nAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma\nPHASE1\n2023-04-26\n2024-07-31\n22\n2025-04-30\n\n\nNCT04952597\nBeiGene\nüü¢ No Change\nCOMPLETED\nLimited Stage Small Cell Lung Cancer\nPHASE2\n2021-07-15\n2023-07-26\n126\n2024-10-23\n\n\nNCT05805501\nHoffmann-La Roche\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nRenal Cell Carcinoma\nPHASE2\n2023-04-21\n2026-07-31\n199\n2025-11-12\n\n\nNCT03447678\nFondazione IRCCS Istituto Nazionale dei Tumori, Milano\nüü¢ No Change\nUNKNOWN\nNon Small Cell Lung Cancer (NSCLC)\nPHASE2\n2018-05-23\n2022-05-31\n65\n2021-06-08\n\n\nNCT04672369\nInnovent Biologics (Suzhou) Co.¬†Ltd.\nüü¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-06-06\n2023-06-01\n42\n2023-06-18\n\n\nNCT04672356\nInnovent Biologics (Suzhou) Co.¬†Ltd.\nüü¢ No Change\nCOMPLETED\nAdvanced Lung Cancer\nPHASE1\n2021-01-25\n2023-06-01\n19\n2023-06-18\n\n\nNCT05009069\nHoffmann-La Roche\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nRectal Neoplasms, Rectal Cancer\nPHASE2\n2022-03-18\n2026-11-06\n58\n2026-01-16\n\n\nNCT04353830\nInnovent Biologics (Suzhou) Co.¬†Ltd.\nüü¢ No Change\nCOMPLETED\nAdvanced Malignancies\nPHASE1\n2020-05-22\n2022-05-11\n34\n2023-02-28\n\n\nNCT07337447\nHospices Civils de Lyon\nüü¢ No Change\nNOT_YET_RECRUITING\nCarcinoma, Neuroendocrine\nPHASE2\n2026-04\n2030-04\n122\n2026-01-07\n\n\nNCT04354246\nCompugen Ltd\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC\nPHASE1\n2020-03-31\n2025-12-30\n110\n2025-05-18\n\n\nNCT04933227\nHoffmann-La Roche\nüü¢ No Change\nTERMINATED\nStomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma\nPHASE2\n2021-08-06\n2023-11-17\n29\n2024-11-11\n\n\nNCT05414032\nUniversity Health Network, Toronto\nüü¢ No Change\nRECRUITING\nLocoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)\nPHASE2\n2023-07-12\n2026-07\n200\n2025-03-25\n\n\nNCT06003621\nOmico\nüü¢ No Change\nRECRUITING\nSolid Tumor, Adult\nPHASE2\n2023-12-15\n2028-11-01\n96\n2024-11-13\n\n\nNCT05568095\nArcus Biosciences, Inc.\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Upper Gastrointestinal Tract Adenocarcinoma\nPHASE3\n2022-11-21\n2026-06\n1040\n2026-01-30\n\n\nNCT06777628\nIRCCS Azienda Ospedaliero-Universitaria di Bologna\nüü¢ No Change\nRECRUITING\nLiver Cancer, Adult\nN/A\n2024-09-15\n2028-10-15\n100\n2025-01-14\n\n\nNCT06773481\nSichuan Luzhou Buchang Biopharmaceutical Co., Ltd.\nüü¢ No Change\nRECRUITING\nGlioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM), Glioblastoma WHO Grade IV\nPHASE1\n2025-04-07\n2026-12\n40\n2025-07-07\n\n\nNCT03708224\nAlain Algazi\nüü¢ No Change\nRECRUITING\nCancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer\nPHASE2\n2019-03-08\n2028-06-30\n55\n2025-01-24\n\n\nNCT03652402\nAssistance Publique - H√¥pitaux de Paris\nüü¢ No Change\nCOMPLETED\nKidney Transplant Rejection, Kidney Transplantation, Risk Stratification, Prognosis\nN/A\n2018-11-27\n2021-10-28\n558\n2024-06-04\n\n\nNCT03486119\nYonsei University\nüü¢ No Change\nCOMPLETED\nNon -Small Cell Lung Cancer\nN/A\n2018-02-05\n2020-07-07\n60\n2020-10-14\n\n\nNCT05120375\nBio-Thera Solutions\nüü¢ No Change\nTERMINATED\nSolid Tumor\nPHASE1\n2022-02-17\n2023-04-07\n5\n2023-10-08\n\n\nNCT05327530\nEMD Serono Research & Development Institute, Inc.\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nLocally Advanced or Metastatic Urothelial Carcinoma\nPHASE2\n2022-08-17\n2026-06-25\n256\n2026-01-23\n\n\nNCT04570839\nCompugen Ltd\nüü¢ No Change\nCOMPLETED\nEndometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer\nPHASE1, PHASE2\n2020-08-31\n2024-05-15\n48\n2024-07-17\n\n\nNCT05520294\nUniversity of Colorado, Denver\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nN/A\n2022-09-01\n2024-08-31\n90\n2024-04-15\n\n\nNCT05417321\nShanghai Huaota Biopharmaceutical Co., Ltd.\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor, NSCLC\nPHASE1, PHASE2\n2022-08-25\n2025-08-01\n80\n2025-01-02\n\n\nNCT06328036\nNational Cancer Institute (NCI)\nüü¢ No Change\nWITHDRAWN\nRecurrent Glioblastoma, IDH-Wildtype\nPHASE2\n2025-04-30\n2025-07-01\n0\n2024-12-27\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nüü¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT04262856\nArcus Biosciences, Inc.\nüü¢ No Change\nCOMPLETED\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2020-05-28\n2025-07-09\n151\n2025-08-25\n\n\nNCT04736173\nArcus Biosciences, Inc.\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer\nPHASE2\n2021-02-08\n2027-05\n169\n2025-12-09\n\n\nNCT05126537\nSoutheast University, China\nüü¢ No Change\nUNKNOWN\n28 Day Mortality\nN/A\n2022-01-01\n2022-12-31\n100\n2022-11-25\n\n\nNCT05289492\niTeos Therapeutics\nüü¢ No Change\nTERMINATED\nMultiple Myeloma\nPHASE1\n2022-05-01\n2023-11-29\n16\n2024-10-23\n\n\nNCT07115043\nAstraZeneca\nüü¢ No Change\nRECRUITING\nMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma\nPHASE1, PHASE2\n2025-07-29\n2029-10-02\n60\n2025-12-18\n\n\nNCT05743504\nNational Taiwan University Hospital\nüü¢ No Change\nUNKNOWN\nLocally Advanced Esophageal Squamous Cell Carcinoma\nPHASE1, PHASE2\n2023-09-18\n2025-11-30\n32\n2024-01-31\n\n\nNCT05073484\nBio-Thera Solutions\nüü¢ No Change\nTERMINATED\nAdvanced Solid Tumor\nPHASE1\n2021-10-29\n2023-03-30\n13\n2023-10-09\n\n\nNCT07376512\nCentre Georges Francois Leclerc\nüü¢ No Change\nNOT_YET_RECRUITING\nNon-Small Cell Lung Cancer, Melanoma (Skin Cancer)\nN/A\n2026-03-01\n2030-03-01\n378\n2026-01-22\n\n\nNCT05904886\nHoffmann-La Roche\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nHepatocellular Carcinoma\nPHASE3\n2023-09-14\n2026-09-01\n687\n2025-12-30\n\n\nNCT03739710\nGlaxoSmithKline\nüü¢ No Change\nCOMPLETED\nNeoplasms\nPHASE2\n2019-01-24\n2024-05-02\n175\n2025-06-13\n\n\nNCT04791839\nWashington University School of Medicine\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nNon Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer\nPHASE2\n2021-08-04\n2030-06-30\n30\n2025-11-04\n\n\nNCT05020912\nCase Comprehensive Cancer Center\nüü¢ No Change\nRECRUITING\nBasal Cell Carcinoma\nPHASE2\n2021-12-13\n2027-12\n28\n2025-11-25\n\n\nNCT06334406\nCentre Hospitalier Universitaire de Besancon\nüü¢ No Change\nNOT_YET_RECRUITING\nBladder Cancer\nN/A\n2024-04-02\n2026-04-02\n33\n2024-03-19\n\n\nNCT07343310\nKine Sciences Co., Ltd.\nüü¢ No Change\nCOMPLETED\nCIDP - Chronic Inflammatory Demyelinating Polyneuropathy\nPHASE1\n2024-08-27\n2025-04-14\n9\n2026-01-15\n\n\nNCT03342417\nExcellaBio LLC\nüü¢ No Change\nTERMINATED\nBreast Cancer Female, Ovarian Cancer, Gastric Cancer\nPHASE2\n2018-02-14\n2019-05-29\n5\n2021-11-05\n\n\nNCT04682665\nUniversity of Leeds\nüü¢ No Change\nCOMPLETED\nColon Cancer Liver Metastasis\nN/A\n2021-09-16\n2024-07-31\n81\n2024-12-03\n\n\nNCT05123482\nAstraZeneca\nüü¢ No Change\nRECRUITING\nBreast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer\nPHASE1, PHASE2\n2021-10-18\n2027-09-29\n460\n2025-12-02\n\n\nNCT07161414\nAstraZeneca\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-11-25\n2029-07-24\n40\n2025-12-18\n\n\nNCT07015164\nAssistance Publique - H√¥pitaux de Paris\nüü¢ No Change\nNOT_YET_RECRUITING\nHIV\nN/A\n2025-06-10\n2026-09-11\n80\n2025-06-03\n\n\nNCT05702229\nAstraZeneca\nüü¢ No Change\nRECRUITING\nGastric Cancer\nPHASE2\n2023-01-16\n2027-09-28\n240\n2025-11-14\n\n\nNCT07213882\nAssistance Publique - H√¥pitaux de Paris\nüü¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT03628677\nArcus Biosciences, Inc.\nüü¢ No Change\nCOMPLETED\nSolid Tumor, Unspecified, Adult\nPHASE1\n2018-09-12\n2025-01-23\n75\n2025-02-03\n\n\nNCT06897436\nMedical University of Lublin\nüü¢ No Change\nNOT_YET_RECRUITING\nEndometriosis\nN/A\n2025-05-01\n2029-12-31\n60\n2025-03-24\n\n\nNCT05633927\nHospitales Universitarios Virgen del Roc√≠o\nüü¢ No Change\nCOMPLETED\nSARS-CoV-2 RNA Vaccines, HIV Infection\nN/A\n2021-04-01\n2022-12-01\n48\n2024-10-09\n\n\nNCT04836507\nCurocell Inc.\nüü¢ No Change\nRECRUITING\nRelapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)\nPHASE1, PHASE2\n2021-03-02\n2028-02\n91\n2021-04-29\n\n\nNCT05775159\nAstraZeneca\nüü¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Biliary Tract Cancer\nPHASE2\n2023-04-24\n2027-10-28\n294\n2025-11-12\n\n\nNCT06338657\nUniversity of Southern California\nüü¢ No Change\nTERMINATED\nHead and Neck Squamous Cell Carcinoma\nPHASE1\n2024-04-01\n2025-09-09\n1\n2025-09-09\n\n\nNCT06860815\nCity of Hope Medical Center\nüü¢ No Change\nRECRUITING\nAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the Liver\nPHASE2\n2026-04-01\n2027-01-30\n11\n2026-01-27\n\n\nNCT04624828\nIstituto Clinico Humanitas\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nOligorecurrent and Oligoprogressive Prostate Cancer Patients\nNA\n2020-10-19\n2026-07\n40\n2025-04-22\n\n\nNCT05574335\nNational Institute of Allergy and Infectious Diseases (NIAID)\nüü¢ No Change\nTERMINATED\nType 1 Diabetes Mellitus\nPHASE1, PHASE2\n2023-04-26\n2025-10-20\n8\n2026-01-05\n\n\nNCT06302556\nFondazione IRCCS Ca‚Äô Granda, Ospedale Maggiore Policlinico\nüü¢ No Change\nNOT_YET_RECRUITING\nLung Transplant Rejection\nN/A\n2024-04\n2026-02\n280\n2024-03-06\n\n\nNCT04761198\nMereo BioPharma\nüü¢ No Change\nCOMPLETED\nSolid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor\nPHASE1, PHASE2\n2021-03-23\n2023-10-30\n76\n2025-03-07\n\n\nNCT04693234\nBeiGene\nüü¢ No Change\nCOMPLETED\nCervical Cancer\nPHASE2\n2021-02-15\n2023-08-31\n178\n2025-04-09\n\n\nNCT03563716\nGenentech, Inc.\nüü¢ No Change\nCOMPLETED\nNon-small Cell Lung Cancer\nPHASE2\n2018-08-10\n2025-11-24\n135\n2025-12-30\n\n\nNCT07324642\nKine Sciences Co., Ltd.\nüü¢ No Change\nCOMPLETED\nHealthy Volunteers\nPHASE1\n2025-05-26\n2025-08-25\n24\n2025-12-24\n\n\nNCT05809895\nNovartis Pharmaceuticals\nüü¢ No Change\nWITHDRAWN\nTriple Negative Breast Cancer\nPHASE2\n2023-09-15\n2029-07-18\n0\n2023-07-21\n\n\nNCT04732494\nBeiGene\nüü¢ No Change\nCOMPLETED\nEsophageal Squamous Cell Carcinoma\nPHASE2\n2021-03-31\n2023-12-26\n125\n2024-12-23\n\n\nNCT05645692\nHoffmann-La Roche\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nUrothelial Cancer\nPHASE2\n2023-04-13\n2026-12-31\n204\n2026-01-28\n\n\nNCT04457778\nEMD Serono Research & Development Institute, Inc.\nüü¢ No Change\nCOMPLETED\nMetastatic Solid Tumors\nPHASE1\n2020-07-10\n2023-06-23\n58\n2023-12-07\n\n\nNCT03772899\nLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St.¬†Joseph‚Äôs\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1\n2019-03-27\n2026-08\n20\n2025-03-26\n\n\nNCT04374877\nCoherus Oncology, Inc.\nüü¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer\nPHASE1\n2020-04-22\n2025-06-05\n145\n2025-11-06\n\n\nNCT06346197\nCentre Leon Berard\nüü¢ No Change\nRECRUITING\nGastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer\nPHASE3\n2025-12-08\n2028-05-15\n132\n2025-12-19\n\n\nNCT05780073\nFundaci√≥ Institut Germans Trias i Pujol\nüü¢ No Change\nCOMPLETED\nHIV Infection Primary\nPHASE2\n2023-10-16\n2025-04-01\n60\n2025-09-16\n\n\nNCT03667716\nCompugen Ltd\nüü¢ No Change\nCOMPLETED\nAdvanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer\nPHASE1\n2018-09-06\n2024-01-30\n121\n2025-01-15\n\n\nNCT06784947\nUniversity of Colorado, Denver\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nMicrosatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV\nPHASE2\n2025-03-25\n2028-05\n13\n2025-10-01\n\n\nNCT05014815\nBeiGene\nüü¢ No Change\nCOMPLETED\nLocally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV\nPHASE2\n2021-11-16\n2024-09-04\n272\n2025-08-28\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nüü¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT04746924\nBeiGene\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nNon-small Cell Lung Cancer, NSCLC\nPHASE3\n2021-06-08\n2026-03-31\n662\n2025-06-23\n\n\nNCT07098338\nAstraZeneca\nüü¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE2\n2025-08-07\n2029-04-06\n278\n2025-09-25\n\n\nNCT06532539\nShandong Cancer Hospital and Institute\nüü¢ No Change\nRECRUITING\nEndometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis\nPHASE2\n2024-06-13\n2026-05\n30\n2024-07-29\n\n\nNCT06864598\nPeking University People‚Äôs Hospital\nüü¢ No Change\nENROLLING_BY_INVITATION\nGraft-versus-host Disease (GVHD)\nN/A\n2025-01-09\n2026-10-31\n100\n2025-03-04\n\n\nNCT03661047\nMassachusetts General Hospital\nüü¢ No Change\nWITHDRAWN\nColon Cancer\nPHASE2\n2019-11-30\n2021-11-30\n0\n2021-11-10\n\n\nNCT04866017\nBeiGene\nüü¢ No Change\nTERMINATED\nNon Small Cell Lung Cancer\nPHASE3\n2021-06-17\n2023-10-17\n63\n2024-10-09\n\n\nNCT05127824\nJodi Maranchie\nüü¢ No Change\nRECRUITING\nCarcinoma, Renal Cell\nPHASE2\n2023-07-06\n2026-12\n42\n2025-04-30\n\n\nNCT04303169\nMerck Sharp & Dohme LLC\nüü¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-09-24\n146\n2025-10-23\n\n\nNCT05329766\nArcus Biosciences, Inc.\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nGastrointestinal Tract Malignancies\nPHASE2\n2022-06-10\n2027-06\n332\n2026-01-27\n\n\nNCT04323202\nCase Comprehensive Cancer Center\nüü¢ No Change\nCOMPLETED\nBasal Cell Carcinoma of the Head and Neck\nPHASE1\n2020-08-04\n2025-06-25\n13\n2025-10-23\n\n\nNCT07221253\nAstraZeneca\nüü¢ No Change\nRECRUITING\nBiliary Tract Cancer\nPHASE3\n2025-12-04\n2029-07-04\n1100\n2026-01-07\n\n\nNCT05676931\nGilead Sciences\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Non-Small Cell Lung Cancer\nPHASE2\n2023-02-21\n2027-12\n400\n2025-09-29\n\n\nNCT06790706\nHospices Civils de Lyon\nüü¢ No Change\nRECRUITING\nPeritoneal Mesothelioma, Gestational Trophoblastic Tumor, Thymoma and Thymic Carcinoma, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor\nPHASE2\n2025-10-01\n2031-06\n154\n2025-10-01\n\n\nNCT04543617\nHoffmann-La Roche\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2020-09-28\n2027-03-31\n760\n2026-01-16\n\n\nNCT04305041\nMerck Sharp & Dohme LLC\nüü¢ No Change\nCOMPLETED\nMelanoma\nPHASE1, PHASE2\n2020-06-26\n2025-08-25\n100\n2025-08-28\n\n\nNCT06996782\nAstraZeneca\nüü¢ No Change\nRECRUITING\nAdvanced or Metastatic Non-small Cell Lung Cancer\nPHASE1, PHASE2\n2025-11-24\n2029-02-23\n152\n2026-01-13\n\n\nNCT05665595\nMerck Sharp & Dohme LLC\nüü¢ No Change\nCOMPLETED\nMelanoma\nPHASE3\n2023-01-19\n2025-09-26\n1594\n2025-10-03\n\n\nNCT06868277\nAstraZeneca\nüü¢ No Change\nRECRUITING\nCarcinoma, Non-Small Cell Lung\nPHASE3\n2025-04-10\n2030-12-02\n830\n2026-01-12\n\n\nNCT06692738\nAstraZeneca\nüü¢ No Change\nRECRUITING\nNon-small Cell Lung Cancer\nPHASE3\n2024-11-18\n2029-10-08\n880\n2026-01-20\n\n\nNCT04774484\nFrancesc Marti\nüü¢ No Change\nWITHDRAWN\nEnd Stage Renal Disease\nNA\n2023-01\n2026-06-30\n0\n2023-02-10\n\n\nNCT04256421\nHoffmann-La Roche\nüü¢ No Change\nCOMPLETED\nSmall Cell Lung Cancer\nPHASE3\n2020-02-04\n2025-07-31\n490\n2026-01-09\n\n\nNCT06989112\nAstraZeneca\nüü¢ No Change\nRECRUITING\nEndometrial Cancer\nPHASE3\n2025-03-27\n2031-02-19\n600\n2026-01-14\n\n\nNCT05816460\nUniversity College Dublin\nüü¢ No Change\nUNKNOWN\nInsomnia, Cancer\nNA\n2023-05-22\n2024-06-10\n308\n2023-05-19\n\n\nNCT06627647\nAstraZeneca\nüü¢ No Change\nRECRUITING\nNon-squamous Non-small Cell Lung Cancer\nPHASE3\n2024-11-27\n2030-03-25\n878\n2025-12-19\n\n\nNCT04305054\nMerck Sharp & Dohme LLC\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nMelanoma\nPHASE1, PHASE2\n2020-07-01\n2026-04-20\n315\n2025-08-28\n\n\nNCT04294810\nHoffmann-La Roche\nüü¢ No Change\nCOMPLETED\nNon-Small Cell Lung Cancer\nPHASE3\n2020-03-04\n2025-12-30\n620\n2026-01-29\n\n\nNCT03198546\nSecond Affiliated Hospital of Guangzhou Medical University\nüü¢ No Change\nRECRUITING\nHepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nüü¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT04585815\nPfizer\nüü¢ No Change\nTERMINATED\nCarcinoma, Non-Small-Cell Lung\nPHASE1, PHASE2\n2020-11-10\n2024-10-29\n34\n2025-12-18\n\n\nNCT02443155\nNovo Nordisk A/S\nüü¢ No Change\nCOMPLETED\nDiabetes, Diabetes Mellitus, Type 1\nPHASE2\n2015-11-10\n2019-02-27\n308\n2021-03-10\n\n\n\nDownload Status Summary (CSV)"
  },
  {
    "objectID": "targets/tigit.html#visual-summary",
    "href": "targets/tigit.html#visual-summary",
    "title": "TIGIT",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nDownload Full Data (CSV)"
  },
  {
    "objectID": "targets/tigit.html#change-history",
    "href": "targets/tigit.html#change-history",
    "title": "TIGIT",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-05 15:27:28\nInitial data collection: 133 trials found.\n\n\n\nNo specific trial changes (beyond initial collection) recorded yet for tigit."
  },
  {
    "objectID": "targets/b7-h3.html",
    "href": "targets/b7-h3.html",
    "title": "B7-H3",
    "section": "",
    "text": "Note\n\n\n\nB7-H3 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ"
  },
  {
    "objectID": "targets/b7-h3.html#monitoring-status",
    "href": "targets/b7-h3.html#monitoring-status",
    "title": "B7-H3",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT07358260\nRobbie Majzner\nüü¢ No Change\nNOT_YET_RECRUITING\nPediatric Solid Tumor, Neuroblastoma\nPHASE1\n2026-06\n2031-12-31\n40\n2026-01-14\n\n\nNCT06500819\nCrystal Mackall, MD\nüü¢ No Change\nRECRUITING\nNeuroblastoma, Sarcoma, Osteosarcoma\nPHASE1\n2024-07-11\n2029-07\n41\n2025-04-18\n\n\nNCT05515185\nThe First People‚Äôs Hospital of Lianyungang\nüü¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nEARLY_PHASE1\n2022-09-09\n2024-09-08\n30\n2022-08-23\n\n\nNCT06778603\nPeking University People‚Äôs Hospital\nüü¢ No Change\nRECRUITING\nOsteosarcoma, Resection Margins, B7-H3 Probe, Local Recurrence\nPHASE1, PHASE2\n2024-01-01\n2026-12-31\n32\n2025-01-11\n\n\nNCT05942456\nPeking University People‚Äôs Hospital\nüü¢ No Change\nRECRUITING\nBiomarker, Progression, Osteosarcoma, Surveillance\nN/A\n2023-06-05\n2024-12-31\n200\n2024-05-11\n\n\nNCT04077866\nSecond Affiliated Hospital, School of Medicine, Zhejiang University\nüü¢ No Change\nUNKNOWN\nRecurrent Glioblastoma, Refractory Glioblastoma\nPHASE1, PHASE2\n2023-06-01\n2025-08-01\n40\n2022-12-25\n\n\nNCT05474378\nStanford University\nüü¢ No Change\nRECRUITING\nBrain and Nervous System\nPHASE1\n2022-07-12\n2026-08\n39\n2025-10-10\n\n\nNCT04897321\nSt.¬†Jude Children‚Äôs Research Hospital\nüü¢ No Change\nRECRUITING\nPediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma\nPHASE1\n2022-07-06\n2027-03-01\n32\n2025-10-23\n\n\nNCT06158139\nUNC Lineberger Comprehensive Cancer Center\nüü¢ No Change\nRECRUITING\nPancreas Cancer, Relapse, Resistant Cancer\nPHASE1\n2024-07-18\n2028-06\n27\n2025-03-14\n\n\nNCT04385173\nSecond Affiliated Hospital, School of Medicine, Zhejiang University\nüü¢ No Change\nUNKNOWN\nRecurrent Glioblastoma, Refractory Glioblastoma\nPHASE1\n2022-12-01\n2024-05-01\n12\n2022-12-25\n\n\nNCT05835687\nSt.¬†Jude Children‚Äôs Research Hospital\nüü¢ No Change\nRECRUITING\nCentral Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, High Grade Glioma, Glioblastoma, Medulloblastoma\nPHASE1\n2023-04-27\n2028-03\n48\n2026-01-15\n\n\nNCT02628535\nMacroGenics\nüü¢ No Change\nTERMINATED\nMesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma\nPHASE1\n2015-09\n2019-11-25\n67\n2022-02-04\n\n\nNCT07222735\nSt.¬†Jude Children‚Äôs Research Hospital\nüü¢ No Change\nRECRUITING\nSarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma\nPHASE1\n2025-12-05\n2031-11-05\n42\n2025-11-18\n\n\nNCT06018363\nDushu Lake Hospital Affiliated to Soochow University\nüü¢ No Change\nRECRUITING\nBrain Gliomas, High-Grade Gliomas, GBM\nPHASE1, PHASE2\n2023-06-01\n2027-12-31\n25\n2025-08-13\n\n\nNCT06646627\nStanford University\nüü¢ No Change\nRECRUITING\nOvarian Cancer\nPHASE1\n2024-11-11\n2025-12\n48\n2025-07-07\n\n\nNCT06347068\nUNC Lineberger Comprehensive Cancer Center\nüü¢ No Change\nRECRUITING\nBreast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer\nPHASE1\n2024-06-27\n2028-05\n42\n2025-09-15\n\n\nNCT04432649\nShenzhen Geno-Immune Medical Institute\nüü¢ No Change\nUNKNOWN\nSolid Tumor\nPHASE1, PHASE2\n2020-06-01\n2024-05-31\n100\n2020-06-11\n\n\nNCT02982941\nMacroGenics\nüü¢ No Change\nCOMPLETED\nNeuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor\nPHASE1\n2016-12\n2019-05-22\n25\n2022-02-04\n\n\nNCT05562024\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nüü¢ No Change\nRECRUITING\nB7-H3-positive Relapsed/ Refractory Neuroblastoma\nPHASE1\n2022-12-30\n2039-02-18\n24\n2023-02-23\n\n\nNCT04670068\nUNC Lineberger Comprehensive Cancer Center\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nEpithelial Ovarian Cancer\nPHASE1\n2021-01-27\n2030-02\n4\n2025-12-04\n\n\nNCT05241392\nBeijing Tiantan Hospital\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nGlioblastoma\nPHASE1\n2022-01-27\n2026-12-31\n30\n2025-02-09\n\n\nNCT03406949\nMacroGenics\nüü¢ No Change\nCOMPLETED\nAdvanced Solid Tumors\nPHASE1\n2018-02-27\n2022-04-27\n25\n2022-05-18\n\n\nNCT05366179\nUNC Lineberger Comprehensive Cancer Center\nüü¢ No Change\nRECRUITING\nGlioblastoma Multiforme\nPHASE1\n2022-09-02\n2030-05-30\n36\n2025-10-16\n\n\nNCT07172958\nChildren‚Äôs National Research Institute\nüü¢ No Change\nRECRUITING\nRhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor\nPHASE1\n2026-01-27\n2038-12\n18\n2026-01-26\n\n\nNCT06454955\nPeking University Cancer Hospital & Institute\nüü¢ No Change\nRECRUITING\nB7H3, CD276 Affibody, PET/CT Imaing\nEARLY_PHASE1\n2024-01-01\n2026-11-30\n50\n2024-08-21\n\n\nNCT05752877\nSecond Affiliated Hospital of Soochow University\nüü¢ No Change\nRECRUITING\nAdvanced Glioma, Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy\nNA\n2021-05-01\n2026-04-30\n12\n2023-03-02\n\n\nNCT05190185\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nüü¢ No Change\nUNKNOWN\nMalignant Melanoma, Lung Cancer, or Colorectal Cancer\nPHASE1\n2021-06-01\n2023-12-01\n18\n2021-12-29\n\n\nNCT03198052\nSecond Affiliated Hospital of Guangzhou Medical University\nüü¢ No Change\nRECRUITING\nLung Cancer, Cancer, Immunotherapy, CAR-T Cell\nPHASE1\n2017-07-01\n2036-08-01\n30\n2024-06-22\n\n\nNCT06951243\nBeijing GoBroad Hospital\nüü¢ No Change\nNOT_YET_RECRUITING\nAdvanced Extrapulmonary Neuroendocrine Cancer\nPHASE2\n2025-05-06\n2028-05-06\n40\n2025-04-22\n\n\nNCT06305299\nUNC Lineberger Comprehensive Cancer Center\nüü¢ No Change\nRECRUITING\nOvary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent\nPHASE1\n2024-07-29\n2026-03\n27\n2025-09-12\n\n\nNCT07189871\nRadiopharm Theranostics, Ltd\nüü¢ No Change\nRECRUITING\nCastration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)\nPHASE1, PHASE2\n2026-02\n2027-12\n61\n2026-01-13\n\n\nNCT05731219\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nüü¢ No Change\nUNKNOWN\nRelapsed/Refractory Acute Myeloid Leukemia\nPHASE1\n2022-09-26\n2025-09-26\n18\n2023-02-15\n\n\nNCT06169904\nShanghai Zhongshan Hospital\nüü¢ No Change\nCOMPLETED\nUrothelial Carcinoma\nN/A\n2012-01-25\n2022-11-22\n215\n2023-12-12\n\n\nNCT02381314\nMacroGenics\nüü¢ No Change\nCOMPLETED\nMelanoma, Non Small Cell Lung Cancer\nPHASE1\n2015-03-26\n2018-09-26\n24\n2022-02-04\n\n\nNCT01918930\nMacroGenics\nüü¢ No Change\nTERMINATED\nMelanoma\nPHASE1\n2013-07\n2016-10\n6\n2022-02-04\n\n\nNCT05722171\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nüü¢ No Change\nUNKNOWN\nRelapsed/Refractory Acute Myeloid Leukemia\nEARLY_PHASE1\n2022-12-27\n2024-12-27\n10\n2023-01-31\n\n\nNCT07268053\nNader Sanai\nüü¢ No Change\nNOT_YET_RECRUITING\nGlioblastoma (GBM), Brain Metastasases\nEARLY_PHASE1\n2026-01\n2029-07\n15\n2026-01-20\n\n\nNCT05143151\nShenzhen University General Hospital\nüü¢ No Change\nUNKNOWN\nAdvanced Pancreatic Carcinoma\nPHASE1, PHASE2\n2021-07-01\n2024-07\n10\n2021-12-02\n\n\nNCT04315246\nY-mAbs Therapeutics\nüü¢ No Change\nWITHDRAWN\nLeptomeningeal Metastasis, Solid Tumor, Adult\nPHASE1, PHASE2\n2022-08-31\n2024-12-31\n0\n2022-07-12\n\n\nNCT04185038\nSeattle Children‚Äôs Hospital\nüü¢ No Change\nRECRUITING\nCentral Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma, Medulloblastoma, Childhood, Germ Cell Tumor, Atypical Teratoid/Rhabdoid Tumor, Primitive Neuroectodermal Tumor, Choroid Plexus Carcinoma, Pineoblastoma, Childhood, Glioma\nPHASE1\n2019-12-11\n2041-05\n90\n2025-12-05\n\n\nNCT07099898\nGlaxoSmithKline\nüü¢ No Change\nRECRUITING\nNeoplasms, Lung\nPHASE3\n2025-08-11\n2028-09-11\n300\n2026-01-20\n\n\nNCT04167618\nY-mAbs Therapeutics\nüü¢ No Change\nTERMINATED\nMedulloblastoma, Childhood\nPHASE1, PHASE2\n2021-09-30\n2022-08-11\n2\n2023-09-11\n\n\nNCT05768880\nSeattle Children‚Äôs Hospital\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm\nPHASE1\n2023-05-05\n2043-12-31\n72\n2025-11-17\n\n\nNCT06699576\nHansoh BioMedical R&D Company\nüü¢ No Change\nNOT_YET_RECRUITING\nOsteosarcoma, Soft Tissue Sarcoma (STS)\nPHASE1\n2024-12-20\n2028-12-30\n448\n2024-11-19\n\n\nNCT06825624\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nMetastatic Colorectal Cancer (CRC)\nPHASE1\n2024-10-03\n2026-12-31\n560\n2025-02-09\n\n\nNCT06112704\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE2\n2024-02-06\n2026-12-31\n220\n2024-11-27\n\n\nNCT05280470\nDaiichi Sankyo\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nExtensive-stage Small-cell Lung Cancer\nPHASE2\n2022-03-09\n2026-12-15\n187\n2025-10-24\n\n\nNCT06912152\nZhejiang University\nüü¢ No Change\nRECRUITING\nB7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors\nPHASE1\n2025-05-12\n2028-12-31\n12\n2025-05-19\n\n\nNCT06426680\nInnolake Biopharm\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1\n2024-10-30\n2026-03\n240\n2024-12-04\n\n\nNCT02475213\nMacroGenics\nüü¢ No Change\nCOMPLETED\nMelanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma\nPHASE1\n2015-07\n2021-08-18\n146\n2025-08-04\n\n\nNCT06482905\nTcelltech Inc.\nüü¢ No Change\nRECRUITING\nHigh-grade Glioma, WHO Grade ‚Ö£ Glioma\nPHASE1\n2024-09-04\n2027-06\n52\n2026-01-05\n\n\nNCT06892548\nBioNTech SE\nüü¢ No Change\nRECRUITING\nAdvanced Lung Cancer\nPHASE1, PHASE2\n2025-05-02\n2031-06\n594\n2026-01-19\n\n\nNCT04129320\nMacroGenics\nüü¢ No Change\nWITHDRAWN\nHead and Neck Cancer, Squamous Cell Carcinoma of Head and Neck\nPHASE2, PHASE3\n2019-10\n2022-10\n0\n2022-02-04\n\n\nNCT07256782\nQilu Pharmaceutical Co., Ltd.\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1, PHASE2\n2025-10-24\n2028-05\n444\n2025-11-25\n\n\nNCT03729596\nMacroGenics\nüü¢ No Change\nTERMINATED\nSquamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer\nPHASE1, PHASE2\n2018-11-21\n2023-03-18\n143\n2025-07-10\n\n\nNCT06332170\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1\n2024-04-26\n2028-05-30\n610\n2024-07-16\n\n\nNCT05830123\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nOsteosarcoma, Sarcoma\nPHASE2\n2023-06-08\n2027-12-31\n170\n2024-08-22\n\n\nNCT02456571\nDuke University\nüü¢ No Change\nCOMPLETED\nProstate Cancer\nN/A\n2016-11\n2019-06-13\n38\n2019-07-08\n\n\nNCT07115446\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nAdvanced Prostate Cancer\nPHASE1\n2025-08-19\n2028-12\n63\n2025-11-28\n\n\nNCT06203210\nDaiichi Sankyo\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nSmall Cell Lung Cancer\nPHASE3\n2024-05-21\n2029-02-22\n540\n2026-01-15\n\n\nNCT06007729\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nHead and Neck Squamous Cell Carcinoma\nPHASE2\n2023-12-18\n2027-12-12\n170\n2024-08-19\n\n\nNCT04637503\nShenzhen Geno-Immune Medical Institute\nüü¢ No Change\nUNKNOWN\nNeuroblastoma\nPHASE1, PHASE2\n2020-11-18\n2023-12-31\n100\n2020-11-18\n\n\nNCT06052423\nHansoh BioMedical R&D Company\nüü¢ No Change\nWITHDRAWN\nExtensive Stage Small Cell Lung Cancer (ES-SCLC)\nPHASE2\n2024-11-30\n2027-06-30\n0\n2024-03-01\n\n\nNCT06242470\nMacroGenics\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)\nPHASE1\n2024-03-06\n2028-10\n250\n2026-01-08\n\n\nNCT06780137\nMerck Sharp & Dohme LLC\nüü¢ No Change\nRECRUITING\nSmall Cell Lung Cancer\nPHASE1, PHASE2\n2025-02-27\n2030-02-14\n242\n2026-02-03\n\n\nNCT05276609\nShanghai Hansoh Biomedical Co., Ltd\nüü¢ No Change\nUNKNOWN\nAdvanced Solid Tumor\nPHASE1\n2021-11-28\n2023-12-31\n177\n2023-02-13\n\n\nNCT07227597\nMerck Sharp & Dohme LLC\nüü¢ No Change\nNOT_YET_RECRUITING\nSmall Cell Lung Cancer Extensive Stage\nPHASE1, PHASE2\n2026-01-14\n2030-11-29\n170\n2025-12-29\n\n\nNCT07386002\nT-MAXIMUM Pharmaceutical Inc\nüü¢ No Change\nNOT_YET_RECRUITING\nGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype\nPHASE2\n2026-06-30\n2029-07-31\n40\n2026-01-27\n\n\nNCT05063357\nY-mAbs Therapeutics\nüü¢ No Change\nWITHDRAWN\nDIPG\nPHASE1\n2022-03\n2026-12\n0\n2023-06-22\n\n\nNCT06776198\nPeking University People‚Äôs Hospital\nüü¢ No Change\nNOT_YET_RECRUITING\nOsteosarcoma, Transcriptome, Tumor Microenvironment, Precision Medicine\nN/A\n2025-03-01\n2027-06-01\n100\n2025-01-21\n\n\nNCT04842812\nSecond Affiliated Hospital of Guangzhou Medical University\nüü¢ No Change\nRECRUITING\nLiver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer, Brain Tumor, Solid Tumor, Adult, PD1, CTLA4\nPHASE1\n2021-01-01\n2035-01-01\n40\n2024-06-22\n\n\nNCT06001255\nHansoh BioMedical R&D Company\nüü¢ No Change\nRECRUITING\nMetastasis Castration Resistant Prostate Cancer(mCRPC)\nPHASE2\n2024-01-18\n2025-12-31\n120\n2024-08-19\n\n\nNCT06330064\nDaiichi Sankyo\nüü¢ No Change\nRECRUITING\nRecurrent or Metastatic Solid Tumors\nPHASE2\n2024-04-10\n2028-07-25\n520\n2026-01-14\n\n\nNCT07231081\nTcelltech Inc.\nüü¢ No Change\nRECRUITING\nSolid Tumors\nPHASE1\n2025-10-16\n2027-12-20\n85\n2025-11-13\n\n\nNCT05064306\nMemorial Sloan Kettering Cancer Center\nüü¢ No Change\nNO_LONGER_AVAILABLE\nCentral Nervous System/Leptomeningeal Neoplasms\nN/A\nN/A\nN/A\nN/A\n2025-07-29\n\n\nNCT05142189\nBioNTech SE\nüü¢ No Change\nRECRUITING\nNon-Small Cell Lung Cancer\nPHASE1\n2022-06-17\n2031-11\n280\n2025-11-10\n\n\nNCT06362252\nDaiichi Sankyo\nüü¢ No Change\nRECRUITING\nExtensive Stage-small Cell Lung Cancer\nPHASE1, PHASE2\n2024-07-22\n2026-12-30\n123\n2025-10-08\n\n\nNCT06372236\nPeking University\nüü¢ No Change\nCOMPLETED\nConditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor\nPHASE1\n2023-12-05\n2025-05-08\n10\n2025-08-07\n\n\nNCT06954246\nQilu Pharmaceutical Co., Ltd.\nüü¢ No Change\nRECRUITING\nSmall Cell Lung Cancer Extensive Stage\nPHASE3\n2025-06-04\n2028-04\n450\n2025-06-15\n\n\nNCT04634825\nMacroGenics\nüü¢ No Change\nTERMINATED\nHead and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma\nPHASE2\n2021-03-17\n2022-07-29\n62\n2023-12-18\n\n\nNCT05991583\nSUNHOÔºàChinaÔºâBioPharmaceutical CO., Ltd.\nüü¢ No Change\nRECRUITING\nAdvanced Malignant Tumors\nPHASE1, PHASE2\n2023-07-03\n2025-12-30\n25\n2025-01-15\n\n\nNCT07076095\nSUNHOÔºàChinaÔºâBioPharmaceutical CO., Ltd.\nüü¢ No Change\nNOT_YET_RECRUITING\nSmall Cell Lung Cancer\nPHASE2\n2025-08-01\n2031-08-01\n200\n2025-07-17\n\n\nNCT04864821\nPersonGen BioTherapeutics (Suzhou) Co., Ltd.\nüü¢ No Change\nUNKNOWN\nOsteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer\nEARLY_PHASE1\n2021-05-14\n2023-05-14\n24\n2021-04-30\n\n\nNCT05914116\nDualityBio Inc.\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumors\nPHASE1, PHASE2\n2023-08-17\n2028-05\n862\n2025-11-18\n\n\nNCT07004647\nRuijin Hospital\nüü¢ No Change\nRECRUITING\nPeritoneal Tumor\nNA\n2025-03-15\n2028-11-30\n10\n2025-05-26\n\n\nNCT07181473\nPhrontline Biopharma\nüü¢ No Change\nRECRUITING\nLung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies\nPHASE1\n2025-08-25\n2027-09-15\n200\n2026-01-08\n\n\nNCT05293496\nMacroGenics\nüü¢ No Change\nCOMPLETED\nAdvanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma\nPHASE1\n2022-04-19\n2025-08-26\n31\n2025-10-09\n\n\nNCT06742593\nSuzhou Maximum Bio-tech Co., Ltd.\nüü¢ No Change\nNOT_YET_RECRUITING\nBrain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors\nPHASE1\n2025-01-01\n2026-12-30\n12\n2024-12-17\n\n\nNCT04630769\nMasonic Cancer Center, University of Minnesota\nüü¢ No Change\nCOMPLETED\nOvarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer\nPHASE1\n2021-04-02\n2022-01-01\n3\n2023-03-27\n\n\nNCT04544592\nUniversity of Colorado, Denver\nüü¢ No Change\nRECRUITING\nB-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma\nPHASE1, PHASE2\n2021-03-10\n2026-07\n45\n2025-04-29\n\n\nNCT02883595\nSun Yat-sen University\nüü¢ No Change\nCOMPLETED\nSepsis\nPHASE4\n2016-03-31\n2016-12-31\n20\n2019-04-02\n\n\nNCT00554515\nBeth Israel Deaconess Medical Center\nüü¢ No Change\nCOMPLETED\nMetastatic Renal Cell Carcinoma\nPHASE2\n2006-11\n2013-10-31\n123\n2024-08-07\n\n\nNCT02204020\nUniversity of Pittsburgh\nüü¢ No Change\nWITHDRAWN\nAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)\nPHASE2\n2015-04\n2016-05-04\n0\n2018-03-29\n\n\nNCT02937844\nBeijing Sanbo Brain Hospital\nüü¢ No Change\nUNKNOWN\nGlioblastoma Multiforme\nPHASE1\n2016-07\n2019-07\n20\n2016-10-17\n\n\nNCT06644781\nDaiichi Sankyo\nüü¢ No Change\nRECRUITING\nEsophageal Squamous Cell Carcinoma\nPHASE3\n2025-03-27\n2029-11-01\n510\n2026-01-09\n\n\nNCT05562869\nNantes University Hospital\nüü¢ No Change\nRECRUITING\nChronic Kidney Failure\nPHASE3\n2024-05-03\n2027-05-03\n30\n2024-05-07\n\n\nNCT04013620\nNantes University Hospital\nüü¢ No Change\nUNKNOWN\nChronic Kidney Failure\nPHASE3\n2020-09-01\n2022-07-09\n48\n2020-03-30\n\n\nNCT04276701\nUniversity Hospital, Bordeaux\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nSystemic Lupus Erythematosus\nNA\n2021-03-10\n2027-03\n500\n2026-01-30\n\n\nNCT07136558\nBeijing InnoCare Pharma Tech Co., Ltd.\nüü¢ No Change\nNOT_YET_RECRUITING\nAdvanced Solid Tumors\nPHASE1\n2025-08\n2030-12\n410\n2025-08-20\n\n\nNCT06953089\nDualityBio Inc.\nüü¢ No Change\nRECRUITING\nSolid Tumors\nPHASE2\n2025-07-18\n2030-06-30\n492\n2025-08-27\n\n\nNCT02584517\nUniversity of Oxford\nüü¢ No Change\nWITHDRAWN\nTemporal Arteritis\nN/A\n2016-01\n2021-01\n0\n2022-08-10\n\n\nNCT07307053\nCancer Institute and Hospital, Chinese Academy of Medical Sciences\nüü¢ No Change\nNOT_YET_RECRUITING\nRare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors\nPHASE1, PHASE2\n2026-01-01\n2031-01-31\n600\n2025-12-13\n\n\nNCT06993766\nKing Faisal Specialist Hospital & Research Center\nüü¢ No Change\nNOT_YET_RECRUITING\nRelapsed B-ALL, CAR T-cells, CD19-directed CAR T-cell Therapy\nN/A\n2025-05-20\n2030-05-31\n100\n2025-05-19\n\n\nNCT02923180\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nProstate Cancer\nPHASE2\n2017-02-14\n2026-07\n33\n2025-07-10\n\n\nNCT06014255\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nüü¢ No Change\nRECRUITING\nProstate Cancer\nPHASE2\n2024-02-16\n2029-03-01\n219\n2025-10-28\n\n\nNCT04465643\nSidney Kimmel Comprehensive Cancer Center at Johns Hopkins\nüü¢ No Change\nCOMPLETED\nNerve Sheath Tumors\nPHASE1\n2021-06-08\n2025-07-30\n13\n2025-10-02\n\n\nNCT06221553\nChulalongkorn University\nüü¢ No Change\nRECRUITING\nDIPG Brain Tumor, Diffuse Intrinsic Pontine Glioma\nPHASE1\n2024-03-01\n2026-09-01\n9\n2025-03-27\n\n\nNCT06612645\nChulalongkorn University\nüü¢ No Change\nRECRUITING\nPediatric Cancers, Solid Tumor Pediatric\nPHASE1\n2025-04-01\n2027-12-01\n9\n2025-04-01\n\n\nNCT04514484\nNational Cancer Institute (NCI)\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Renal Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, HIV Infection, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Kaposi Sarcoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Kaposi Sarcoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Urothelial Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8\nPHASE1\n2021-11-22\n2025-11-02\n18\n2025-10-25\n\n\nNCT04743661\nPediatric Brain Tumor Consortium\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nRecurrent Medulloblastoma, Recurrent Ependymoma\nPHASE2\n2022-04-04\n2030-10-30\n62\n2024-08-02\n\n\nNCT03014804\nJonsson Comprehensive Cancer Center\nüü¢ No Change\nWITHDRAWN\nGiant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma\nPHASE2\n2019-12-01\n2022-12-01\n0\n2020-07-22\n\n\n\nDownload Status Summary (CSV)"
  },
  {
    "objectID": "targets/b7-h3.html#visual-summary",
    "href": "targets/b7-h3.html#visual-summary",
    "title": "B7-H3",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nDownload Full Data (CSV)"
  },
  {
    "objectID": "targets/b7-h3.html#change-history",
    "href": "targets/b7-h3.html#change-history",
    "title": "B7-H3",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-05 17:03:12\nInitial data collection: 111 trials found.\n\n\n\nNo specific trial changes (beyond initial collection) recorded yet for b7-h3."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch is an automated monitoring system designed to track changes in clinical trials related to selected therapeutic targets (e.g., CCR8, TIGIT, IgE). By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the competitive landscape."
  },
  {
    "objectID": "about.html#project-overview",
    "href": "about.html#project-overview",
    "title": "About",
    "section": "",
    "text": "Clinical Trial Watch is an automated monitoring system designed to track changes in clinical trials related to selected therapeutic targets (e.g., CCR8, TIGIT, IgE). By leveraging the ClinicalTrials.gov API v2, this project provides researchers and clinicians with a clear, up-to-date view of the competitive landscape."
  },
  {
    "objectID": "about.html#key-features",
    "href": "about.html#key-features",
    "title": "About",
    "section": "Key Features",
    "text": "Key Features\n\nAutomated Monitoring: Daily updates on the status and key parameters of clinical trials for multiple targets.\nChange Detection: Intelligent diffing engine that highlights meaningful changes in recruitment status, phase, and completion dates.\nData Insights: Interactive visualizations to help understand clinical trial trends and distributions for each target.\nOpen Data: All consolidated raw data is available for download as a CSV for deeper analysis."
  },
  {
    "objectID": "about.html#how-it-works",
    "href": "about.html#how-it-works",
    "title": "About",
    "section": "How it Works",
    "text": "How it Works\n\nDaily Watch: A GitHub Actions workflow runs every 24 hours to fetch the latest data for all NCT IDs listed in trials.yaml.\nAnalysis: The src/main.py script compares current data with previous snapshots to identify any changes.\nReport Generation: Updates are logged in the history.qmd page, and the dashboard is refreshed with the latest summary stats.\nPublishing: The updated Quarto website is automatically published to GitHub Pages."
  },
  {
    "objectID": "about.html#data-source",
    "href": "about.html#data-source",
    "title": "About",
    "section": "Data Source",
    "text": "Data Source\nAll data is sourced from ClinicalTrials.gov via their official API.\n\nThis project is built using Python, Quarto, and GitHub Actions."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "ÏûÑÏÉÅÏãúÌóòÏùÑ ÌÉÄÍ≤üÎ≥ÑÎ°ú Î™®ÎãàÌÑ∞ÎßÅÌï©ÎãàÎã§.\n\n\n\nTarget\nDescription\nTrials\nChanged\n\n\n\n\nCCR8\nCCR8 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n12\nüü¢ 0\n\n\nTIGIT\nTIGIT ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n133\nüü¢ 0\n\n\nIgE\nÍ∑∏ÎÉ• ÌÖåÏä§Ìä∏Ïö©\n3\nüü¢ 0\n\n\nB7-H3\nB7-H3 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n111\nüü¢ 0"
  },
  {
    "objectID": "index.html#targets-overview",
    "href": "index.html#targets-overview",
    "title": "Clinical Trial Watch",
    "section": "",
    "text": "ÏûÑÏÉÅÏãúÌóòÏùÑ ÌÉÄÍ≤üÎ≥ÑÎ°ú Î™®ÎãàÌÑ∞ÎßÅÌï©ÎãàÎã§.\n\n\n\nTarget\nDescription\nTrials\nChanged\n\n\n\n\nCCR8\nCCR8 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n12\nüü¢ 0\n\n\nTIGIT\nTIGIT ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n133\nüü¢ 0\n\n\nIgE\nÍ∑∏ÎÉ• ÌÖåÏä§Ìä∏Ïö©\n3\nüü¢ 0\n\n\nB7-H3\nB7-H3 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ\n111\nüü¢ 0"
  },
  {
    "objectID": "targets/ige.html",
    "href": "targets/ige.html",
    "title": "IgE",
    "section": "",
    "text": "Note\n\n\n\nÍ∑∏ÎÉ• ÌÖåÏä§Ìä∏Ïö©"
  },
  {
    "objectID": "targets/ige.html#monitoring-status",
    "href": "targets/ige.html#monitoring-status",
    "title": "IgE",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT02546921\nCancer Research UK\nüü¢ No Change\nCOMPLETED\nHuman Cancers\nPHASE1\n2016-02-16\n2021-07-30\n26\n2022-07-15\n\n\nNCT03019237\nMedical University of Vienna\nüü¢ No Change\nCOMPLETED\nAllergy\nNA\n2012-11\n2013-05\n15\n2017-01-10\n\n\nNCT06547840\nEpsilogen Ltd\nüü¢ No Change\nRECRUITING\nAdvanced Ovarian Cancer, Platinum-resistant Ovarian Cancer\nPHASE1\n2024-09-03\n2027-03\n45\n2025-06-18\n\n\n\nDownload Status Summary (CSV)"
  },
  {
    "objectID": "targets/ige.html#visual-summary",
    "href": "targets/ige.html#visual-summary",
    "title": "IgE",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nDownload Full Data (CSV)"
  },
  {
    "objectID": "targets/ige.html#change-history",
    "href": "targets/ige.html#change-history",
    "title": "IgE",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-05 15:28:42\nInitial data collection: 267 trials found.\n\n\n\nNo specific trial changes (beyond initial collection) recorded yet for ige."
  },
  {
    "objectID": "targets/ccr8.html",
    "href": "targets/ccr8.html",
    "title": "CCR8",
    "section": "",
    "text": "Note\n\n\n\nCCR8 ÌÉÄÍ≤ü ÏûÑÏÉÅÏãúÌóò Î™®ÎãàÌÑ∞ÎßÅ"
  },
  {
    "objectID": "targets/ccr8.html#monitoring-status",
    "href": "targets/ccr8.html#monitoring-status",
    "title": "CCR8",
    "section": "Monitoring Status",
    "text": "Monitoring Status\n\n\n\nTrial ID\nSponsor\nUpdate\nStatus\nConditions\nPhases\nStart\nEnd\nEnroll\nLast Updated\n\n\n\n\nNCT05101070\nShionogi\nüü¢ No Change\nRECRUITING\nSolid Tumors\nPHASE1, PHASE2\n2022-05-30\n2027-04-16\n274\n2025-05-22\n\n\nNCT07362186\nLaNova Medicines Limited\nüü¢ No Change\nNOT_YET_RECRUITING\nLocally Advanced or Metastatic GC and GCJ Adenocarcinoma\nPHASE3\n2026-04-03\n2028-09-28\n400\n2026-01-15\n\n\nNCT06387628\nFudan University\nüü¢ No Change\nRECRUITING\nTNBC - Triple-Negative Breast Cancer\nPHASE2\n2024-07-10\n2027-04-01\n74\n2024-08-01\n\n\nNCT07213882\nAssistance Publique - H√¥pitaux de Paris\nüü¢ No Change\nNOT_YET_RECRUITING\nCutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome\nEARLY_PHASE1\n2026-01-01\n2028-08-01\n30\n2025-10-02\n\n\nNCT05537740\nBayer\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumors\nPHASE1\n2022-10-11\n2027-05-04\n129\n2026-01-21\n\n\nNCT05007782\nGilead Sciences\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor\nPHASE1\n2021-08-18\n2028-12\n416\n2025-12-26\n\n\nNCT07205718\nTakeda\nüü¢ No Change\nRECRUITING\nAdvanced or Metastatic Solid Tumors\nPHASE1, PHASE2\n2025-11-19\n2029-12-21\n223\n2025-11-28\n\n\nNCT05635643\nCoherus Oncology, Inc.\nüü¢ No Change\nRECRUITING\nAdvanced Solid Tumor, Head and Neck Squamous Cell Carcinoma\nPHASE1\n2022-12-15\n2026-02\n87\n2025-07-30\n\n\nNCT05935098\nBeiGene\nüü¢ No Change\nACTIVE_NOT_RECRUITING\nAdvanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor\nPHASE1\n2023-08-21\n2027-03-31\n263\n2025-06-23\n\n\nNCT06657144\nCoherus Oncology, Inc.\nüü¢ No Change\nRECRUITING\nMetastatic Solid Tumor, Advanced Solid Tumor\nPHASE1\n2025-04-01\n2027-05\n154\n2026-01-12\n\n\nNCT06620822\nShanghai Pulmonary Hospital, Shanghai, China\nüü¢ No Change\nNOT_YET_RECRUITING\nNon Small Cell Lung Cancer\nPHASE2\n2024-09-30\n2027-09-30\n296\n2024-09-28\n\n\nNCT07226856\nMayo Clinic\nüü¢ No Change\nRECRUITING\nMetastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8\nPHASE2\n2025-12-12\n2028-12-01\n43\n2025-12-19\n\n\n\nDownload Status Summary (CSV)"
  },
  {
    "objectID": "targets/ccr8.html#visual-summary",
    "href": "targets/ccr8.html#visual-summary",
    "title": "CCR8",
    "section": "Visual Summary",
    "text": "Visual Summary\n\nStatus & PhaseTop Sponsors\n\n\n\n\n                            \n                                            \n\n\n\n\n                            \n                                            \n\n\n\n\n\n\n                            \n                                            \n\n\n\n\n\nDownload Full Data (CSV)"
  },
  {
    "objectID": "targets/ccr8.html#change-history",
    "href": "targets/ccr8.html#change-history",
    "title": "CCR8",
    "section": "Change History",
    "text": "Change History\n\nTarget MilestonesTrial Changes\n\n\nDate: 2026-02-05 15:26:51\nInitial data collection: 12 trials found.\n\n\n\nNo specific trial changes (beyond initial collection) recorded yet for ccr8."
  }
]